Physician profile
Indi Vasudeva
NPI 1629074596
$7,789.99
in general payments reported to CMS, 2019-2025
24 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.79 · 2020: $129 · 2021: $459 · 2022: $1,129 · 2023: $650 · 2024: $4,039 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121 · Consulting Fee: $2,850 · Education: $34.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,121.23 |
| Consulting Fee | $2,850.00 |
| Education | $34.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $3,140.37 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $1,052.13 | 2021-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $540.91 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $529.91 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $511.59 | 2021-2025 | Krystexxa, Uplizna |
| Aurinia Pharma U.S., INC. | $383.94 | 2022-2025 | Lupkynis |
| Horizon Therapeutics Plc | $358.05 | 2021-2023 | Krystexxa |
| Corcept Therapeutics | $357.94 | 2025 | Korlym |
| Travere Therapeutics, INC. | $269.25 | 2023-2025 | |
| Akebia Therapeutics INC | $117.17 | 2020-2024 | Auryxia |
| Novartis Pharmaceuticals Corporation | $101.83 | 2023-2025 | |
| Vifor Pharma, INC. | $92.82 | 2020-2021 | |
| Inari Medical, INC. | $51.98 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ardelyx, INC. | $45.42 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $31.54 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.89 | 2023 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $27.40 | 2024 | Crysvita |
| Mallinckrodt Enterprises LLC | $27.29 | 2019 | |
| Medtronic, INC. | $24.80 | 2023 | Intellis Adaptivestim |
| Novo Nordisk INC | $23.98 | 2021 | |
| Ets Wound Care LLC | $20.94 | 2024 | Mirragen Advanced Wound Matrix |
| Otsuka America Pharmaceutical, INC. | $18.80 | 2019 | |
| Cormedix INC. | $16.49 | 2024 | Defencath |
| Ani Pharmaceuticals, INC. | $15.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indi Vasudeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.